In contrast to PB B cells from healthy individuals, CLL B cells express multiple activation markers, including CD38, CD23, CD25, CD69, and CD71 [34, 35], and stimulation of PB lymphocytes with TLR agonists induces NETosis-like death of B cells [33]. Here, FCER2 is linked to B-cell chronic lymphocytic leukemia.